IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 6, April 2024

Exploring Knowledge about Anti -Viral Medicines

Bhagyashree Desale, Pallavi Bule, Samruddhi Chinchpure, Shraddha Karale, Dr. S. V. Datkhile
Samarth Institute of Pharmacy, Belhe, Maharashtra, India

Abstract: *Antiviral drugs have revolutionized the treatment of viral infections, but their use is not without risks. This comprehensive review examines the toxicities associated with a range of antiviral drugs used in clinical practice. The objective is to provide healthcare professionals with a consolidated overview of potential adverse effects and their management. Antiviral drugs have transformed the treatment of viral infections, yet their efficacy comes with a price the potential for adverse effects. This review provides an extensive examination of the toxicities associated with various antiviral drugs, shedding light on the critical balance between therapeutic benefit and patient safety. The side effect and toxicity of these drugs have to be known and if these happened then appropriate to choose another antiviral treatment that have less side effect and toxicity for patient if needed.*

Keywords: Toxicity, side effects, Antiviral drugs

REFERENCES

[1]. BMC Biology 15 1 – 6.(PMC free composition)(PubMed)(Google Scholar)
[2]. Champe HRAPC, Fisher BD.(2007) Lippincott's Illustrated Reviews Microbiology. PhiladelphiaLippincott Williams & Wilkins.(Google Scholar) 3.
[3]. Saxena SK, Saxena S, Saxena R, etal.(2010) Arising trends, challenges and prospects in antiviral cures and medicine development for contagious conditions.
[4]. Electronic Journal of Biology 6 26 – 31.(Google Scholar) 4. De Clercq E, LiG.(2016) Approved antiviral medicines over the formerly 50 times. Clinical Microbiology Reviews 29 695 – 747.(PMC free composition)(PubMed)(Google Scholar) 5.
[5]. HeH.(2013) Vaccines and antiviral agents. Current Issues in Molecular Virology Viral Genetics and Biotechnological Applications 2013 239 – 250.(Google Scholar) 6. Parks JM, Smith JC.(2020) How to discover antiviral medicines snappily.
[6]. The New England Journal of Medicine 382(23) 2261 – 2264.(PubMed)(Google Scholar) 7. Shin W- J, Seong BL.(2019) new antiviral medicine discovery strategies to attack medicine- resistant mutants of influenza contagion strains.
[7]. Expert Opinion on Drug Discovery 14 153 – 168.(PubMed)(Google Scholar)
[8]. Asiri YI, Alsayari A, Muhsinah AB, etal.(2020) Benzothiazoles as implicit antiviral agents. Journal of Pharmacy and Pharmacology 72 1459 – 1480.
[9]. PMC free composition)(PubMed)(Google Scholar) 9. Ryu W-S.(2017) Contagion life cycle. Molecular Virology of Human Pathogenic Contagions 2017 31 – 45.(Google Scholar) 10. Connolly SA, Jackson JO, Jardetzky TS, etal.(2011) Fusing structure and serve a structural view of the herpesvirus entry ministry.
[10]. Nature Reviews Microbiology 9 369 – 381.(PMC free composition)(PubMed)(Google Scholar) 11.BalfourHH., JR(1983) Resistance of herpes simplex to acyclovir. Annals of Internal Medicine 98 404 – 406.(PubMed)(Google Scholar) 12.
[11]. Fyfe J, Keller P, Furman P, etal.(1978) Thymidine kinase from herpes simplex contagion phosphorylates the new antiviral emulsion, 9-(2- hydroxyethoxymethyl) guanine
[12]. The Journal of Biological Chemistry 253 8721 – 8727.(PubMed)(Google Scholar) 13. Derse D, Cheng Y, Furman P, etal.(1981) Inhibition of purified mortal and herpes simplex contagion- convinced DNA polymerases by 9-(2- hydroxyethoxymethyl) guanine triphosphate. goods on manual- template function.
[13]. The Journal of Biological Chemistry 256 11447 – 11451.(PubMed)(Google Scholar) 14. Furman PA, St, Clair M, SpectorT.(1984) Acyclovir triphosphate is a tone- murder inactivator of the herpes simplex contagion DNA polymerase.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 6, April 2024

[14]. The Journal of Biological Chemistry 259 9575 – 9579.(PubMed)(Google Scholar) 15. de Miranda P, BlumMR.(1983) Pharmacokinetics of acyclovir after intravenous and oral administration. The Journal of Antimicrobial Chemotherapy 12 29 – 37.

[15]. (PubMed)(Google Scholar) 16. Balfour HH, Jr, Chace BA, Stapleton JT, etal.(1989) A randomized, placebo- controlled trial of oral acyclovir for the forestallment of cytomegalovirus complaint in donors of renal allografts. The New England Journal of Medicine 320 1381 – 1387.(PubMed)(Google Scholar) 17.

[16]. Fletcher C, Englund J, Edelman C, etal.(1991) Pharmacologic base for high- cure oral acyclovir prophylaxis of cytomegalovirus complaint in renal allograft donors.

[17]. Antimicrobial Agents and Chemotherapy 35 938 – 943.(PMC free composition)(PubMed)(Google Scholar) 18.

[18]. Meyers JD, Wade JC, Mitchell CD, etal.(1982) Multicenter cooperative trial of intravenous acyclovir for treatment of mucocutaneous herpes simplex contagion infection in the immunocompromised host.

[19]. The American Journal of Medicine 73 229 – 235.(PubMed)(Google Scholar)

[20]. Soul- Lawton J, Seaber E, On N, etal.(1995) Absolute bioavailability and metabolic disposition of valaciclovir, the L- valyl ester of acyclovir, following oral administration to humans.

[21]. Antimicrobial Agents and Chemotherapy 39 2759 – 2764.(PMC free composition)(PubMed)(Google Scholar) 20. Erice A, Jordan MC, Chace BA, etal.(1987) Ganciclovir treatment of cytomegalovirus complaint in transplant donors and other immunocompromised hosts.

[22]. JAMA 257 3082 – 3087. 1. Balloux F, van DorpL.(2017) Q&A What are pathogens, and what have they done to and for us? BMC Biology 15 1 – 6.(PMC free composition)(PubMed)(Google Scholar) 2.

[23]. Champe HRAPC, Fisher BD.(2007) Lippincott's Illustrated Reviews Microbiology. PhiladelphiaLippincott Williams & Wilkins.(Google Scholar) 3. Saxena SK, Saxena S, Saxena R, etal.(2010) Arising trends, challenges and prospects in antiviral cures and medicine development for contagious conditions.

[24]. Electronic Journal of Biology 6 26 – 31.(Google Scholar) 4. De Clercq E, LiG.(2016) Approved antiviral medicines over the formerly 50 times.

[25]. Clinical Microbiology Reviews 29 695 – 747.(PMC free composition)(PubMed)(Google Scholar)

[26]. HeH.(2013) Vaccines and antiviral agents. Current Issues in Molecular Virology Viral Genetics and Biotechnological Applications 2013 239 – 250.(

[27]. Google Scholar) 6. Parks JM, Smith JC.(2020) How to discover antiviral medicines snappily.

[28]. The New England Journal of Medicine 382(23) 2261 – 2264.(PubMed)(Google Scholar) 7. Shin W- J, Seong BL.(2019) new antiviral medicine discovery strategies to attack medicine- resistant mutants of influenza contagion strains.

[29]. Expert Opinion on Drug Discovery 14 153 – 168.(PubMed)(Google Scholar)

[30]. Asiri YI, Alsayari A, Muhsinah AB, etal.(2020) Benzothiazoles as implicit antiviral agents. Journal of Pharmacy and Pharmacology 72 1459 – 1480.

[31]. (PMC free composition)(PubMed)(Google Scholar) 9. Ryu W-S.(2017) Contagion life cycle. Molecular Virology of Human Pathogenic Contagions 2017 31 – 45.(Google Scholar) 10. Connolly SA, Jackson JO, Jardetzky TS, etal.(2011) Fusing structure and serve a structural view of the herpesvirus entry ministry.

[32]. Nature Reviews Microbiology 9 369 – 381.(PMC free composition)(PubMed)(Google Scholar) 11.

[33]. BalfourHH., JR(1983) Resistance of herpes simplex to acyclovir. Annals of Internal Medicine 98 404 – 406.(PubMed)(Google Scholar) 12. Fyfe J, Keller P, Furman P, etal.(1978) Thymidine kinase from herpes simplex contagion phosphorylates the new antiviral conflation, 9-(2- hydroxyethoxymethyl) guanine.

[34]. The Journal of Biological Chemistry 253 8721 – 8727.(PubMed)(Google Scholar) 13. Derse D, Cheng Y, Furman P, etal.(1981) Inhibition of purified mortal and herpes simplex contagion- convinced DNA polymerases by 9-(2- hydroxyethoxymethyl) guanine triphosphate. goods on homemade- template function.

[35]. The Journal of Biological Chemistry 256 11447 – 11451.(PubMed)(Google Scholar) 14. Furman PA, St, Clair M, SpectorT.(1984) Acyclovir triphosphate is a tone- murder inactivator of the herpes simplex contagion DNA polymerase.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 6, April 2024

[36]. The Journal of Biological Chemistry 259 9575 – 9579.(PubMed)(Google Scholar) 15. de Miranda P, BlumMR.(1983) Pharmacokinetics of acyclovir after intravenous and oral administration. The Journal of Antimicrobial Chemotherapy 12 29 – 37

[37]. PubMed)(Google Scholar) 16. Balfour HH, Jr, Chace BA, Stapleton JT, etal.(1989) A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus complaint in benefactors of renal allografts.

[38]. The New England Journal of Medicine 320 1381 – 1387.(PubMed)(Google Scholar) 17. Fletcher C, Englund J, Edelman C, etal.(1991) Pharmacologic base for high- cure oral acyclovir prophylaxis of cytomegalovirus complaint in renal allograft benefactors

[39]. Antimicrobial Agents and Chemotherapy 35 938 – 943.(PMC free composition)(PubMed)(Google Scholar) 18. Meyers JD, Wade JC, Mitchell CD, etal.(1982) Multicenter collaborative trial of intravenous acyclovir for treatment of mucocutaneous herpes simplex contagion infection in the immunocompromised host.

[40]. The American Journal of Medicine 73 229 – 235.(PubMed)(Google Scholar)

[41]. Soul- Lawton J, Seaber E, On N, etal.(1995) Absolute bioavailability and metabolic disposition of valaciclovir, the L- valyl ester of acyclovir, following oral administration to humans.

[42]. Antimicrobial Agents and Chemotherapy 39 2759 – 2764.(PMC free composition)(PubMed)(Google Scholar) 20. Erice A, Jordan MC, Chace BA, etal.(1987) Ganciclovir treatment of cytomegalovirus complaint in transplant benefactors and other immunocompromised hosts. JAMA 257 3082 – 3087.